Adamantiadi-Behçet syndrome: treatment with recombinant leukocytic interferon

To evaluate efficacy of synthetic leukocytic interferon (SLI) in patients with severe Adamantiadi-Behçet syndrome (ABS). The trial enrolled 18 patients (11 men and 7 women aged 25 to 43 years) with severe ABS. The duration of the disease ranged from 1 to 12 years. Subcutaneous ABS injections in a do...

Full description

Saved in:
Bibliographic Details
Published inTerapevtic̆eskii arhiv Vol. 73; no. 5; p. 43
Main Authors Kacunaros, M, Alicanidu, O, Balacucas, D, Agapakis, D, Palyaleksis, K, Karali, V, Kukurikos, S
Format Journal Article
LanguageRussian
Published Russia (Federation) 2001
Subjects
Adult
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Behcet Syndrome - diagnosis
Behcet Syndrome - drug therapy
Female
Follow-Up Studies
Humans
Interferon Type I - administration & dosage
Interferon Type I - therapeutic use
Male
Recombinant Proteins
Time Factors
Online AccessGet more information

Cover

More Information
Summary:To evaluate efficacy of synthetic leukocytic interferon (SLI) in patients with severe Adamantiadi-Behçet syndrome (ABS). The trial enrolled 18 patients (11 men and 7 women aged 25 to 43 years) with severe ABS. The duration of the disease ranged from 1 to 12 years. Subcutaneous ABS injections in a dose 5 x 10(6) U/m2 for 8 weeks followed by 3 x 10(6) for 16 weeks. The results were estimated by standard clinical and biochemical indices. All 18 patients responded to the treatment. After the course of treatment 13 patients were in remission for 4-52 months. The rest of the patients were given one more course of treatment.
ISSN:0040-3660